CENPV

Across TCGA pan-cancer cohorts, CENPV mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CENPV data layer compared with 26 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CENPV mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CENPV expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where CENPV mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.989	0.696	<.001	62	view →
HNSC	OS	Tertile	IV	0.577	0.886	.011	26	view →
PDAC	OS	Median	II,III,IV	0.891	0.791	.004	17	view →
LSCC	OS	Median	All	0.898	0.695	.006	14	view →
UCEC	OS	Median	II,III,IV	0.620	1.000	.011	12	view →
OV	DFS	Median	All	0.863	1.000	.033	4	view →
GBM	DFS	Median	All	0.827	0.668	.013	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CENPV–CCRCC (OS)

Open the CCRCC breakdown →